Ketamine given by vein with talk therapy for depression that has not improved
Looks at ketamine plus psychotherapy in adults whose depression resisted earlier treatments.
Plain-language title generated from the registry record
Registry title: Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients
Key facts
- Where
- Doorn, NetherlandsSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07706478, who can take part
Where in Netherlands
- SENZDoorn, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Senz
- Trial code
- NCT07706478
- Record updated
- 15 July 2026
- Original description
Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments. The combination of ketamine, psychological support, and integration sessions aims to promote emotional processing, psychological flexibility, and lasting therapeutic change.Read full original descriptionShow less
Effectiveness and Underlying Mechanisms of an Innovative Treatment Program for Persistent Mood and Anxiety Conditions
Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments. The combination of ketamine, psychological support, and integration sessions aims to promote emotional processing, psychological flexibility, and lasting therapeutic change.
Inclusion: Adults (18 years and older); TRD; A MADRS score above the established clinical cut-off, indicating clinically significant depressive symptoms; Insufficient response to at least two adequate antidepressant treatment trials and one evidence-based psychotherapy, or failure to achieve adequate improvement following at least three consecutive treatment steps in accordance with the Dutch Multidisciplinary Guideline for Depression.
Exclusion: Current substance use disorder or recent illicit drug use; Substance use disorder not in remission for at least 3 months; Current or past psychotic disorder; Significant neurological disorders (e.g., epilepsy, elevated intracranial pressure); Uncontrolled hypertension or medical conditions associated with increased cardiovascular or cerebrovascular risk (e.g., aneurysms, recent myocardial infarction or intracerebral hemorrhage); Significant bladder disease (e.g., cystitis); Severe hepatic impairment; Inability to abstain from alcohol for 24 hours before and after treatment; Acute suicidality; Pregnancy, breastfeeding, or ongoing IVF treatment; Extreme underweight or obesity where treatment is deemed medically unsafe Inability to arrange an accompanying adult for transport and support after treatment.